Last reviewed · How we verify
Diamox (ACETAZOLAMIDE)
Diamox (Acetazolamide) is a small molecule carbonic anhydrase inhibitor developed by TEVA BRANDED PHARM and currently owned by the same company. It targets carbonic anhydrase to treat various conditions, including absence seizures, glaucoma, anoxia due to high altitude, and edema. Diamox has been FDA-approved since 1953 and is available as a generic medication due to its off-patent status. The drug has a half-life of 13.0 hours and high bioavailability of 99%. It is used to treat a range of conditions, including those related to fluid retention and high altitude.
At a glance
| Generic name | ACETAZOLAMIDE |
|---|---|
| Sponsor | Teva |
| Drug class | Carbonic Anhydrase Inhibitor [EPC] |
| Target | Carbonic anhydrase |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
| First approval | 1953 |
Approved indications
- Edema due to congestive heart failure
- Drug-induced edema
- Centrencephalic epilepsies
- Chronic simple (open-angle) glaucoma
- Secondary glaucoma
- Preoperative acute angle-closure glaucoma
- Acute mountain sickness prevention
Common side effects
- Metabolic acidosis
- Electrolyte imbalance
- Hepatic insufficiency
- Fulminant hepatic necrosis
- Aplastic anemia
- Agranulocytosis
- Toxic epidermal necrolysis
- Stevens-Johnson syndrome
- Convulsions
- Flaccid paralysis
- Photosensitivity
- Polyuria
Drug interactions
- lithium
Key clinical trials
- Safety and Efficacy of OBX-115 in Advanced Solid Tumors (PHASE1,PHASE2)
- Brain Blood Flow and Sugar Transport in Alzheimer's Disease With and Without Diabetes - A Pilot Imaging Study
- POcus INTERvention for Tailoring Diuretic Strategy in Acute Decompensated Heart Failure (PHASE2,PHASE3)
- Central Sleep Apnea : Physiologic Mechanisms to Inform Treatment (PHASE4)
- Managing Opioid Related Sleep Apnea With Acetazolamide (PHASE2)
- Venous Stenting Evaluation in Patients With Intracranial Hypertension Under Long-term Acetazolamide (NA)
- Preoperative Acetazolamide (PHASE4)
- Stent Implantation Versus Medical Therapy for Idiopathic IntracraniaL Hypertension (SIMPLE) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Diamox CI brief — competitive landscape report
- Diamox updates RSS · CI watch RSS
- Teva portfolio CI